Sensitivity of the NIH Toolbox to Detect Cognitive Change in Individuals With Intellectual and Developmental Disability

Overview

Journal Neurology

Specialty Neurology

Date 2022 Dec 2

PMID 36460468

Authors

Rebecca H Shields

Aaron Kaat

Stephanie M Sansone

Claire Michalak

Jeanine Coleman

Talia Thompson

Forrest J McKenzie

Andrew Dakopolos

Karen Riley

Elizabeth Berry-Kravis

Keith F Widaman

Richard C Gershon

David Hessl

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Individuals with intellectual disability (ID) experience protracted cognitive development compared with typical youth. Sensitive measurement of cognitive change in this population is a critical need for clinical trials and other intervention studies, but well-validated outcome measures are scarce. This study's aim was to evaluate the sensitivity of the NIH Toolbox Cognition Battery (NIHTB-CB) to detect developmental changes in groups with ID-fragile X syndrome (FXS), Down syndrome (DS), and other ID (OID)-and to provide further support for its use as an outcome measure for treatment trials.

Methods: We administered the NIHTB-CB and a reference standard cross-validation measure (Stanford-Binet Intelligence Scales, Fifth Edition [SB5]) to 256 individuals with FXS, DS, and OID (ages 6-27 years). After 2 years of development, we retested 197 individuals. Group developmental changes in each cognitive domain of the NIHTB-CB and SB5 were assessed using latent change score models, and 2-year growth was evaluated at 3 age points (10, 16, and 22 years).

Results: Overall, effect sizes of growth measured by the NIHTB-CB tests were comparable with or exceeded those of the SB5. The NIHTB-CB showed significant gains in almost all domains in OID at younger ages (10 years), with continued gains at 16 years and stability in early adulthood (22 years). The FXS group showed delayed gains in attention and inhibitory control compared with OID. The DS group had delayed gains in receptive vocabulary compared with OID. Unlike the other groups, DS had significant growth in early adulthood in 2 domains (working memory and attention/inhibitory control). Notably, each group's pattern of NIHTB-CB growth across development corresponded to their respective pattern of SB5 growth.

Discussion: The NIHTB-CB is sensitive to developmental changes in individuals with ID. Comparison with levels and timing of growth on the cross-validation measure shows that the NIHTB-CB has potential to identify meaningful trajectories across cognitive domains and ID etiologies. Sensitivity to change within the context of treatment studies and delineation of clinically meaningful changes in NIHTB-CB scores, linked to daily functioning, must be established in future research to evaluate the battery more completely as a key outcome measure.

Citing Articles

Effectiveness of Distant/Remote Blessing Treatment on Cognitive-motor Function: A Randomized Double-blind Placebo-controlled Trial.

Branton A, Trivedi M, Trivedi D, Mondal S, Jana S Health Psychol Res. 2025; 13():128098.

PMID: 39830804 PMC: 11741897. DOI: 10.52965/001c.128098.

Developmental associations between cognition and adaptive behavior in intellectual and developmental disability.

Dakopolos A, Condy E, Smith E, Harvey D, Kaat A, Coleman J J Neurodev Disord. 2024; 16(1):31.

PMID: 38872099 PMC: 11177479. DOI: 10.1186/s11689-024-09542-z.

Developmental Associations between Cognition and Adaptive Behavior in Intellectual and Developmental Disability.

Dakopolos A, Condy E, Smith E, Harvey D, Kaat A, Coleman J Res Sq. 2024; .

PMID: 38260292 PMC: 10802716. DOI: 10.21203/rs.3.rs-3684708/v1.

Mindfulness enhances cognitive functioning: a meta-analysis of 111 randomized controlled trials.

Zainal N, Newman M Health Psychol Rev. 2023; 18(2):369-395.

PMID: 37578065 PMC: 10902202. DOI: 10.1080/17437199.2023.2248222.

Intercorrelation of Molecular Biomarkers and Clinical Phenotype Measures in Fragile X Syndrome.

Aishworiya R, Chi M, Zafarullah M, Mendoza G, Ponzini M, Kim K Cells. 2023; 12(14).

PMID: 37508583 PMC: 10377864. DOI: 10.3390/cells12141920.

References

de la Torre R, de Sola S, Hernandez G, Farre M, Pujol J, Rodriguez J . Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(8):801-810. DOI: 10.1016/S1474-4422(16)30034-5. View

Shields R, Kaat A, McKenzie F, Drayton A, Sansone S, Coleman J . Validation of the NIH Toolbox Cognitive Battery in intellectual disability. Neurology. 2020; 94(12):e1229-e1240. PMC: 7274932. DOI: 10.1212/WNL.0000000000009131. View

Sansone S, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D . Improving IQ measurement in intellectual disabilities using true deviation from population norms. J Neurodev Disord. 2015; 6(1):16. PMC: 4613563. DOI: 10.1186/1866-1955-6-16. View

Boada R, Hutaff-Lee C, Schrader A, Weitzenkamp D, Benke T, Goldson E . Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012; 2:e141. PMC: 3410988. DOI: 10.1038/tp.2012.66. View

Berry-Kravis E, Harnett M, Reines S, Reese M, Ethridge L, Outterson A . Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial. Nat Med. 2021; 27(5):862-870. DOI: 10.1038/s41591-021-01321-w. View

Maulik P, Mascarenhas M, Mathers C, Dua T, Saxena S . Prevalence of intellectual disability: a meta-analysis of population-based studies. Res Dev Disabil. 2011; 32(2):419-36. DOI: 10.1016/j.ridd.2010.12.018. View

Antonarakis S, Skotko B, Rafii M, Strydom A, Pape S, Bianchi D . Down syndrome. Nat Rev Dis Primers. 2020; 6(1):9. PMC: 8428796. DOI: 10.1038/s41572-019-0143-7. View

Berry-Kravis E, Lindemann L, Jonch A, Apostol G, Bear M, Carpenter R . Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov. 2017; 17(4):280-299. PMC: 6904225. DOI: 10.1038/nrd.2017.221. View

Lopez-Bastida J, Oliva-Moreno J . Cost of illness and economic evaluation in rare diseases. Adv Exp Med Biol. 2010; 686:273-82. DOI: 10.1007/978-90-481-9485-8_16. View

10.

Budimirovic D, Berry-Kravis E, Erickson C, Hall S, Hessl D, Reiss A . Updated report on tools to measure outcomes of clinical trials in fragile X syndrome. J Neurodev Disord. 2017; 9:14. PMC: 5467057. DOI: 10.1186/s11689-017-9193-x. View

11.

Esbensen A, Hooper S, Fidler D, Hartley S, Edgin J, Liogier DArdhuy X . Outcome Measures for Clinical Trials in Down Syndrome. Am J Intellect Dev Disabil. 2017; 122(3):247-281. PMC: 5424621. DOI: 10.1352/1944-7558-122.3.247. View

12.

Mccartney K, Burchinal M, Bub K . Best practices in quantitative methods for developmentalists. Monogr Soc Res Child Dev. 2007; 71(3):1-145. DOI: 10.1111/j.1540-5834.2006.07103001.x. View

13.

McArdle J . Latent variable modeling of differences and changes with longitudinal data. Annu Rev Psychol. 2008; 60:577-605. DOI: 10.1146/annurev.psych.60.110707.163612. View

14.

Hagerman R, Berry-Kravis E, Hazlett H, Bailey Jr D, Moine H, Kooy R . Fragile X syndrome. Nat Rev Dis Primers. 2017; 3:17065. DOI: 10.1038/nrdp.2017.65. View

15.

Kaat A, McKenzie F, Shields R, LaForte E, Coleman J, Michalak C . Assessing processing speed among individuals with intellectual and developmental disabilities: A match-to-sample paradigm. Child Neuropsychol. 2021; 28(1):1-13. PMC: 8648883. DOI: 10.1080/09297049.2021.1938987. View

16.

Ghisletta P, McArdle J . Teacher's Corner: Latent Curve Models and Latent Change Score Models Estimated in R. Struct Equ Modeling. 2014; 19(4):651-682. PMC: 4259494. DOI: 10.1080/10705511.2012.713275. View

17.

Erickson C, Davenport M, Schaefer T, Wink L, Pedapati E, Sweeney J . Fragile X targeted pharmacotherapy: lessons learned and future directions. J Neurodev Disord. 2017; 9:7. PMC: 5467059. DOI: 10.1186/s11689-017-9186-9. View

18.

Weintraub S, Bauer P, Zelazo P, Wallner-Allen K, Dikmen S, Heaton R . I. NIH Toolbox Cognition Battery (CB): introduction and pediatric data. Monogr Soc Res Child Dev. 2013; 78(4):1-15. PMC: 3954750. DOI: 10.1111/mono.12031. View

19.

McGrath R, Stransky M, Cooley W, Moeschler J . National profile of children with Down syndrome: disease burden, access to care, and family impact. J Pediatr. 2011; 159(4):535-40.e2. DOI: 10.1016/j.jpeds.2011.04.019. View

20.

Olusanya B, Wright S, Nair M, Boo N, Halpern R, Kuper H . Global Burden of Childhood Epilepsy, Intellectual Disability, and Sensory Impairments. Pediatrics. 2020; 146(1). PMC: 7613313. DOI: 10.1542/peds.2019-2623. View